SYDNEY, Feb 2, 2026, 16:46 AEDT — After-hours update
CSL Limited shares dropped 2.39% to close at A$177.08 on Monday, hitting a low of A$176.18 after opening at A$182.00. The stock remains roughly 36% off its 52-week peak, with around 1.01 million shares traded. Investing.com
CSL has set a firm date for its next big update. The company will release its half-year financial results for 2026 on Wednesday, Feb. 11, followed by an investor and analyst briefing at 10:00 a.m. AEDT. A webcast and same-day replay will be available.
This matters because the stock has been running on a razor-thin margin since last year’s reset. Back in October, the company slashed its fiscal 2026 growth forecast and put the brakes on spinning off its Seqirus vaccines unit, citing weaker U.S. flu shot demand. CEO Paul McKenzie noted, “We have seen a greater decline in influenza vaccination rates in the U.S. than we expected.” The firm also trimmed its net profit after tax and amortisation (NPATA) growth guidance — a key underlying profit metric — on a constant currency basis, which excludes exchange rate effects. Reuters
Monday saw the S&P/ASX 200 slip roughly 1% in a sluggish local session. Trading Economics
CSL stands as a major player in Australia’s market, often viewed by investors as a global revenue generator. Its core drivers — plasma-derived therapies and influenza vaccines — respond directly to overseas demand, while currency fluctuations can complicate the outlook.
CSL’s financial calendar marks Feb. 11 for the interim dividend announcement. The ex-dividend date falls on March 10, meaning shares bought after that won’t qualify for the upcoming payout. The record date is set for March 11, with payments scheduled for April 9. CSL Limited
The watchlist for the half-year results is clear. Investors want to see if there’s any change to full-year guidance, updates on margins and volumes in the plasma business, and whether management’s outlook on Seqirus is showing signs of easing.
CSL put its plans to spin off Seqirus on hold last year. What happens next on that front is unclear. The Feb. 11 briefing should shed light on any timeline or conditions for revisiting the move—if only with a holding statement.
The risk remains that the upcoming update falls short. If vaccine demand remains weak in crucial markets or costs ramp up more than anticipated, management might maintain a cautious outlook, keeping the stock under pressure.
After the regular session wraps up, CSL moves into Tuesday with the market still reacting to headlines and positioning ahead of Feb. 11. The next major event on the calendar is the half-year result and the 10 a.m. briefing.
